AAD 2026: Galderma Showcases Latest Evidence Supporting Its Full-Spectrum, Science-Driven Solutions

From its Therapeutic Dermatology portfolio, Galderma will present data on the efficacy and safety of Nemluvio庐 (nemolizumab) in different patient populations with moderate-to-severe atopic dermatitis, including late-breaking data in pediatric patients, and share four posters on AKLIEF庐 (trifarotene)1-8
Additional presentations related to Dermatological Skincare will explore how artificial intelligence can identify high-risk factors for sensitive skin and Cetaphil庐 in different skin types9
Data from Galderma鈥檚 Injectable Aesthetics portfolio will also show how its hyaluronic acid injectables, Restylane庐, and neuromodulator, RelabotulinumtoxinA*, may address aesthetic needs across the face and d茅colletage10-14
A total of 22 presentations will reinforce the value of Galderma鈥檚 broad and comprehensive portfolio in meeting varied patient needs across Therapeutic Dermatology, Injectable Aesthetics and Dermatological Skincare